CHTR:NASDAQCharter Communications, Inc. Analysis
Data as of 2026-03-11 - not real-time
$219.33
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Charter Communications trades around $219, well below its 20‑day SMA of $232 and far under the 200‑day SMA of $270, indicating a price discount relative to its longer‑term trend. The stock’s trailing P/E of roughly 6x versus an industry average of 18x and a forward P/E near 4.5x signal a deep valuation gap. With a price‑to‑book of 1.73 and a price‑to‑sales under 0.6, the market is pricing CHTR at a fraction of its book and revenue generation. Despite a modest revenue decline of about 2.3%, the company maintains healthy gross (55%) and operating (25%) margins and delivers a 9% net profit margin. Strong cash generation—operating cash flow over $16 billion and free cash flow above $2.7 billion—supports its ability to service debt. However, the balance sheet is heavily leveraged, with a debt‑to‑equity ratio exceeding 480, and cash on hand under $0.5 billion, raising financial risk concerns.
Technical indicators are mixed: RSI sits near 45, MACD histogram is negative and the MACD signal is bearish, while price holds just above a support around $217. Volatility remains elevated at roughly 47% over the past month, and beta is modest, suggesting limited market‑wide price amplification. The “Extreme Greed” sentiment on the fear‑greed index reflects market optimism, yet the lack of dividend and high leverage temper enthusiasm. Analyst consensus is neutral (hold) with an implied upside of about 25%, aligning with the valuation upside potential. In this context, CHTR appears undervalued but carries significant debt‑related risk, making a cautious stance prudent. Investors should monitor debt reduction progress and any forward‑looking earnings guidance before committing larger positions.
Technical indicators are mixed: RSI sits near 45, MACD histogram is negative and the MACD signal is bearish, while price holds just above a support around $217. Volatility remains elevated at roughly 47% over the past month, and beta is modest, suggesting limited market‑wide price amplification. The “Extreme Greed” sentiment on the fear‑greed index reflects market optimism, yet the lack of dividend and high leverage temper enthusiasm. Analyst consensus is neutral (hold) with an implied upside of about 25%, aligning with the valuation upside potential. In this context, CHTR appears undervalued but carries significant debt‑related risk, making a cautious stance prudent. Investors should monitor debt reduction progress and any forward‑looking earnings guidance before committing larger positions.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- High leverage ratio
- Bearish MACD signal
- Price near support
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount
- Strong cash flow generation
- Positive earnings outlook (forward EPS)
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained cash generation
- High ROE relative to peers
- Potential for debt reduction and stable market position
Key Metrics & Analysis
Financial Health
Revenue Growth-2.30%
Profit Margin9.11%
P/E Ratio6.1
ROE28.67%
ROA5.48%
Debt/Equity482.33
P/B Ratio1.7
Op. Cash Flow$16.1B
Free Cash Flow$2.7B
Industry P/E18.2
Technical Analysis
TrendNeutral
RSI44.5
Support$216.92
Resistance$249.24
MA 20$232.55
MA 50$215.80
MA 200$269.90
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Target Price$275.53
Upside/Downside25.63%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.75
Volatility46.57%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.